Market Overview

Transcriptic Selected to Oversee Robotic Cloud Lab Platform for Lilly's San Diego Biotechnology Center

Share:

Transcriptic
announced today that it has entered into a multi-year collaboration
agreement with Eli Lilly and Company whereby Lilly will license the
Transcriptic Common Lab Environment (TCLE) to enable on-demand drug
discovery operations at its San Diego Biotechnology Center. The solution
Transcriptic is developing for Lilly will allow researchers across the
globe to remotely design, synthesize and screen investigational
molecules at the Lilly Life Science Studio (L2S2).

Headquartered in Silicon Valley, Transcriptic created the first robotic
cloud laboratory platform for on-demand life science research. The
company's TCLE integrates laboratory processes, protocols and
instruments together with IoT technologies through a single user
interface to enable robust automation, scalability, flexibility and
remote instrument monitoring.

Using the power of automation along with artificial intelligence and
machine learning, Transcriptic and Lilly will seek to shape the next
generation of drug discovery and expand the reach of individual
scientists to test new ideas, while reducing the cost, accelerating the
speed and minimizing the environmental impact of research activities.

"We are excited to extend the Transcriptic TCLE environment to our San
Diego Biotechnology Center," said Bret Huff, Lilly's Vice President of
Small Molecule Design and Development. "We believe this capability will
transform how new drugs are discovered internally and enhance Lilly's
partnerships with external innovators."

Yvonne Linney PhD, Transcriptic's Chief Executive Officer commented: "We
were impressed with the forward-thinking investment Lilly made in its
Life Science Studio and are excited that the global pharmaceutical
leader chose Transcriptic to power the L2S2 through our platform. Our
mutual goal is to revolutionize drug discovery and find ways to
accelerate the process and increase success. We are confident that the
Transcriptic Common Lab Environment is the right technology platform to
support the next wave of innovation in biotechnology."

"We became early, major investors in Transcriptic because we felt
strongly that leaders in the pharmaceutical industry would demand a
landmark shift in how science drives drug discovery, and that artificial
intelligence and robotics would be key to this industry transformation,"
said Matt Ocko, Managing Partner of DCVC (Data Collective). "The Lilly -
Transcriptic partnership validates DCVC's fundamental investment thesis
in the life sciences."

About Transcriptic

Transcriptic has developed the first robotic cloud laboratory platform
for on-demand life science research. The Transcriptic Common Lab
Environment (TCLE) integrates laboratory processes, protocols and
instruments together with IoT technologies through a single user
interface. Top 10 pharmaceutical as well as growing biotech companies
are using the power of the Transcriptic software platform, either in
their own labs through on-premises deployment of TCLE or externally
through Transcriptic's Bioassay Services. The Transcriptic platform
allows researchers to carry out efficient, reproducible and rapid
experimentation remotely so they can focus on accelerating discoveries
instead of labor-intensive bench work. The company is based in the San
Francisco Bay Area. For more information, visit www.Transcriptic.com.

View Comments and Join the Discussion!